Catherine Derenne

DLA Piper (Brussels)
Senior Associate

Catherine Derenne is Lawyer with DLA Piper in Brussels. She has vast experience in competition law and focuses her practice on a range of EU and multi-jurisdictional competition law matters, including merger control, cartels and State aid.


1768 Bulletin

Bertold Bar-Bouyssière, Catherine Derenne Pharma and Mergers: An overview of EU and national case law


Merger control in the pharmaceutical sector follows the normal pattern of merger analysis, taking account of sectoral specificities. Mergers (used here as a shortcut for all transactions subject to merger control) can involve different types of actors, e.g. manufacturers of branded drugs (’innovators’ or ’originators’), manufacturers of generic drugs, manufacturers of biosimilars, non-manufacturing inventors, universities or start-ups, different categories of wholesalers and distributors, retailers (pharmacies), hospitals, even global investment banks, and the drugs in question can be intended for human or veterinary use. There are also mergers involving manufacturers or distributors of medical equipment, other medical products, or chemicals for use in medicinal products.


Send a message